Skip to main content
Marvel Biosciences Corp. logo

Marvel Biosciences Corp. — Investor Relations & Filings

Ticker · MRVL ISIN · CA57384M1077 TSXV Professional, scientific and technical activities
Open in API
Filings indexed 203 across all filing types
Latest filing 2022-03-30 Regulatory Filings
Country CA Canada
Listing TSXV MRVL

About Marvel Biosciences Corp.

https://marvelbiotechnology.com/

Marvel Biosciences Corp. is a pre-clinical stage biotechnology company specializing in the discovery and development of transformative treatments for complex neurological and neurodevelopmental disorders, including Autism Spectrum Disorder, Rett Syndrome, and Fragile X Syndrome. The company's core strategy involves chemical innovation to create synthetic derivatives of existing approved molecules. This drug redevelopment approach leverages established mechanisms to accelerate development and reduce risk. Its lead candidate, MB-204, is a patented synthetic derivative that has demonstrated preclinical efficacy across these target indications and is currently advancing toward first-in-human studies.

Recent filings

Filing Released Lang Actions
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a Form 52-109FV2 Certification of Interim Filings Venture Issuer Basic Certificate signed by the CEO certifying the accuracy and fair presentation of the interim financial report and interim MD&A for the period ended January 31, 2022. It is a certification letter rather than the interim report itself. The document explicitly states it is a certification and does not contain actual financial statements or substantive financial data. According to the Certification Rule, such officer certifications should be classified as Regulatory Filings (RNS) rather than as the interim report (IR) itself. The document length is short (3057 characters), consistent with a certification letter rather than a full report.
2022-03-30 English
Interim MD&A - English.pdf
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Management’s Discussion and Analysis' (MD&A) and dated March 30, 2022. It references unaudited condensed interim financial statements for the period ended January 31, 2022, and audited consolidated financial statements for the year ended July 31, 2021. The content includes detailed discussion of business strategy, product development, forward-looking statements, and operational milestones. The length is substantial (15,000 characters), and it contains substantive financial and operational analysis rather than just an announcement or certification. The MD&A is a detailed management report explaining financial results and business trends for a period shorter than a full fiscal year (three and six months ended January 31, 2022). Therefore, this document fits the definition of an Interim / Quarterly Report (IR).
2022-03-30 English
Interim financial statements/report – English.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Condensed Interim Consolidated Financial Statements For the Three and Six Months Ended January 31, 2022 and 2021' and contains detailed unaudited financial statements including statements of financial position, loss and comprehensive loss, cash flows, and changes in shareholders' equity. It references compliance with IAS 34 'Interim Financial Reporting' and includes notes to the financial statements. The document is approximately 15,000 characters long, indicating it is a full report rather than a brief announcement. The presence of substantive financial data and analysis for a period shorter than a full fiscal year confirms it is an interim or quarterly report. Therefore, the appropriate classification is Interim / Quarterly Report (IR).
2022-03-30 English
Material change report - English.pdf
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a FORM 51-102F3 - MATERIAL CHANGE REPORT, which reports the proxy tabulation and voting results from the Annual and Special Meeting of Shareholders held on February 15, 2022. It details the election of directors, appointment of auditors, approval of stock option plans, and changes in board composition and committees. The document primarily announces the official voting results and changes in board and management following the meeting. It does not contain full financial statements or detailed financial performance data, nor is it a transcript or presentation. The key content is the official results of shareholder votes and related governance changes. Therefore, this document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length (9434 characters) and detailed voting results support this classification with high confidence.
2022-02-15 English
News release - English.pdf
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a news release announcing the proxy tabulation and shareholder meeting results for Marvel Biosciences Corp. It details the voting outcomes on various motions, election of directors, appointment of auditors, approval of stock option plans, and changes in the board composition. The document does not contain the full annual report or financial statements but reports the results of the shareholder meeting and proxy votes. This matches the definition of a Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is 7766 characters, which is sufficient to contain detailed voting results rather than just a brief announcement. Therefore, the correct classification is DVA with high confidence.
2022-02-15 English
News release - English.pdf
Capital/Financing Update Classification · 90% confidence The document is a corporate update press release from Marvel Biosciences Corp. It provides an overview of the company's strategy, progress on drug development, upcoming milestones, and general business outlook. There are no financial statements, regulatory filings, or detailed financial data presented. The document is not an earnings release, annual report, or interim report. It is a general corporate update aimed at informing shareholders and the market about business progress and future plans. This type of document fits best under the category of Capital/Financing Update (CAP) as it relates to business development and value creation milestones, which are typical in corporate updates about company progress and strategy.
2022-02-08 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.